-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Wanbang (002082.SZ): Mecobalamin obtained EU orphan drug qualification

Zhitongcaijing·11/17/2026 08:17:02
Listen to the news

Zhitong Finance App News, ST Wanbang (002082.SZ) announced that methylcobalamin independently developed by Wanbond Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, was recently certified as an orphan drug by the European Commission (EC) for the treatment of amyotrophic lateral sclerosis (ALS), also known as fever. Previously, methylcobalamin for the treatment of amyotrophic lateral sclerosis had been certified as an orphan drug by the US FDA.

According to reports, methylcobalamin freeze-dried powder injections were approved for the treatment of amyotrophic lateral sclerosis in Japan in September 2024. As of the date of disclosure of the announcement, no methylcobalamin products have been approved for listing with ALS indications in the European Union. Obtaining the EU orphan drug qualification certification this time will help further accelerate the company's strategic layout of pharmaceuticals. After the product is approved for marketing in the EU, it will enjoy incentive policies such as 10-year market exclusivity.